Seed Innov Regulatory News (SEED)

Seed Innovations Ltd / AIM: SEED / Sector: Closed End Investments

12 July 2022

SEED Innovations Limited

("SEED" or the "Company")

Investee Company Update: Little Green Pharma Ltd

SEED Innovations Ltd, the AIM-quoted company investing in fast-growing and industry-leading businesses with a focus on the medical cannabis, health and wellness space, is pleased to note an announcement released on the ASX by its portfolio company, Little Green Pharma Ltd ('LGP').

LGP has signed a two-year medicinal cannabis supply agreement (the 'Agreement') of a non-exclusive LGP white label medicinal cannabis product into Germany worth A$2,000,000 with Ilios Santé GmbH ("Ilios Santé"), a German based licensed pharmaceutical wholesaler and wholly-owned subsidiary of The Bloomwell Group, a leading European medical cannabis healthcare company.

SEED owns 7,324,796 ordinary shares in LGP representing 3.1% of LGP's issued share capital.

Alfredo Pascual, VP of Investment Analysis at SEED, commented:

"Following the release of its strong year end numbers at the beginning of this month, LGP has published further positive progress in Europe with the Agreement with Ilios Santé. This aligns with LGP's key growth strategy and solidifies Little Green Pharma's growing presence as one of the leading global medicinal cannabis suppliers, developing bespoke high-value white label strains in the European Union with its GMP-licensed Danish facility.

"With Ilios Santé and The Bloomwell Group, LGP gains access to a new strategic partner in Germnay, this time one with operations in the supply chain that include treatment and distribution."

The announcement including the material terms of the Agreement can be viewed in full on LGP's website via the following link: https://investor.littlegreenpharma.com/site/investor-centre/asx-announcements

- Ends -

For further information on the Company please visit: www.seedinnovations.com or contact:

Notes 

Seed Innovations Ltd

SEED Innovations is an AIM quoted investment company focused primarily on disruptive high growth life sciences and technology businesses particularly within the medical cannabis arena. The Company's strategy is to identify early-stage opportunities that have an upcoming investment catalyst and grow its portfolio in terms of value whilst limiting the number of investee companies to a level where relevant time can be devoted to each.

 About Little Green Pharma

Little Green Pharma is a global, vertically integrated and geographically diverse medicinal cannabis business with operations from cultivation and production through to manufacturing and distribution. The Company has two global production sites for the manufacture of its own-branded and white-label ranges of GMP-grade medicinal cannabis products, being a 21,500m2 cultivation and 4,000m2 GMP manufacturing facility capable of producing over 20 tonnes of medicinal cannabis biomass per annum located in Denmark (EU) and an indoor cultivation and manufacturing facility located in Western Australia capable of producing ~3 tonnes of medicinal cannabis biomass per annum. Little Green Pharma products comply with all required Danish Medicines Agency and Therapeutic Goods Administration regulations and testing requirements. With a growing range of products containing differing ratios of active ingredients, Little Green Pharma supplies medical-grade cannabis products to Australian, European and overseas markets. The Company has a strong focus on patient access in the emerging global medicinal cannabis market and is actively engaged in promoting education and outreach programs, as well as participating in clinical investigations and research projects to develop innovative new delivery systems. For more information about Little Green Pharma go to: www.littlegreenpharma.com

About Ilios Santé & The Bloomwell Group

 Ilios Santé is an EU Good Distribution Practices (GDP) licensed pharmaceutical wholesaler headquartered in Frankfurt, Germany and a wholly-owned subsidiary of leading German medical cannabis healthcare company, The Bloomwell Group. The Bloomwell Group is a holding company for medical cannabis companies with a mission to build, acquire and invest in ESG healthcare companies along the entire value chain outside of cultivation. As part of the Bloomwell Group, Ilios Santé is part of a fully integrated group of distinct cannabis-related brands, each fulfilling a different purpose, including Ilios Santé in the medicinal cannabis space, Algea Care, Europe's leading telemedicine platform, and Bloomwell's lifestyle brand, Breezy.